title: Plasma concentrations of salbutamol in the treatment of acute asthma in a pediatric emergency. Could age be a parameter of influence?
abstract: OBJECTIVE
  The objective was to determine if the plasma concentrations of salbutamol, obtained during inhalation treatment of infantile acute asthma, are influenced by age range and by the aerosol system used.
  
  
  METHODS
  A randomized clinical trial was conducted in 46 children (1-5 years of age) with a diagnosis of acute asthma crisis, established in an emergency room pediatric service. Twenty-five children received salbutamol using a pressurized metered-dose inhaler with spacer (50 microg/kg), and 21 children received salbutamol by nebulization (150 microg/kg),three times during a 1-h period. At the end of the treatment, one blood sample was drawn and the plasma was stored for later determination of salbutamol concentration (liquid chromatography). Salbutamol plasma concentrations were compared in two age groups (< or =2 years and >2 years of age). The type of device used (pressurized metered-dose inhaler or nebulizer) and the need of hospitalization were also tested. The Mann-Whitney U test was used with the level of significance set at 5% (P < 0.05).
  
  
  RESULTS
  No differences were detected regarding either the aerosol delivery system used or the need for hospitalization in relation to the plasma concentrations of salbutamol. However, higher plasma levels were found in patients >2 years vs patients < or =2 years [median (IQR): 9.40 (6.32-18.22) vs. 4.65 (2.77-10.10) ng/mL], demonstrating a significance difference (P = 0.05).
  
  
  CONCLUSIONS
  Salbutamol plasma concentrations were influenced by age group of the patients submitted to inhalation therapy, even with doses adjusted for body weight. After correcting for the differences in the biovailabilities of the delivery systems, the concentrations were independent of the aerosol delivery device used.
authors.affiliation: Pharmacy, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. elonirotta@hcpa.ufrgs.br
authors.forename: Eloni T
authors.initials: ET
authors.lastname: Rotta
authors.forename: Sérgio L
authors.initials: SL
authors.lastname: Amantéa
authors.forename: Pedro E
authors.initials: PE
authors.lastname: Froehlich
authors.forename: Adriana
authors.initials: A
authors.lastname: Becker
mesh_terms: D000208:Acute Disease; D000280:Administration, Inhalation; D000293:Adolescent; D000367:Age Factors; D000420:Albuterol / Q000008:administration & dosage* / Q000097:blood*; D001249:Asthma / Q000097:blood* / Q000188:drug therapy*; D001835:Body Weight; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D015986:Confounding Factors, Epidemiologic; D004334:Drug Administration Schedule; D004636:Emergency Service, Hospital; D004638:Emergency Treatment / Q000379:methods*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009330:Nebulizers and Vaporizers; D012720:Severity of Illness Index
chemical_list: D001993:Bronchodilator Agents; D000420:Albuterol